Sacituzumab govitecan Medicine 12 June 2019 Extended indication Relapsed/refractory triple-negative breast cancer (TNBC) Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Sacituzumab govitecan Domain Oncology and Hematology Reason of inclusion New medicine (specialité) Main indication Breast cancer Extended indication Relapsed/refractory triple-negative breast cancer (TNBC) Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Immunomedics Portfolio holder Mechanism of action Antibody-drug conjugate Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Fabrikant: Immunomedics. An antibody-drug conjugate comprising hRS7, a humanised antibody that binds to the trophoblast cell-surface antigen (TROP-2), and SN-38 whichis the active metabolite of irinotecan. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date 2020 Expected Registration 2021 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks BTD granted by FDA and preregistration filed. Therapeutic value Current treatment options andere middelen die voor deze indicatie geregisteerd worden: atezolizumab en pembrolizumab Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Median 5.1 month / months Frequency of administration 2 times every 3 weeks Dosage per administration 10 mg/kg References NCT02574455; Bardia et al., N Engl J Med 2019;380:741-51.DOI: 10.1056/NEJMoa1814213. Additional remarks Expected patient volume per year Patient volume 250 - 400 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks In totaal 1.687 diagnoses mammacarcinoom HR-, HER-, waarvan 134 diagnoses stadium 4. Er komen in de loop van de ziekte veel meer patienten in stadium IV; vergelijkbaar met eerdere inschatting pembrolizumab. Schatting experts: 250-400. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Nog geen andere fase III studies maar wel in fase II onderzocht voor: "urothelial cancer, lung cancer, endometrial cancer, prostate cancer". References Additional remarks Other information Additional remarks